Catsoulacos P, Camoutsis C, Papageorgiou A, Adamiak-Margariti E
University of Patras, School of Health Sciences, Greece.
Anticancer Res. 1992 Sep-Oct;12(5):1617-20.
The p-[N,N-bis (2-chloroethyl)amino]phenylacetate esters of 3 beta-hydroxy-N-methyl-17 alpha-aza-D-homo-5 alpha-androstan-17-one and 3 beta-hydroxy-17 alpha-aza-D-homo-5 alpha-androstane have been prepared and their antitumor activity evaluated against L1210 leukemia, P388 leukemia, Ehrlich ascites tumor (EAT) and Lewis Lung Carcinoma (LLC). The results are compared with those of the p-[N,N-bis (2-chloroethyl)amino]phenylacetate of 3 beta-hydroxy-17 alpha-aza-D-homo- 5 alpha-androstan-17-one. The above compounds were also tested in vitro against L1210, P 388, EAT and BHX cell cultures. All compounds were found to be active and their structure-activity relationship is discussed.
已制备出3β-羟基-N-甲基-17α-氮杂-D-高-5α-雄甾烷-17-酮和3β-羟基-17α-氮杂-D-高-5α-雄甾烷的对-[N,N-双(2-氯乙基)氨基]苯乙酸酯,并评估了它们对L1210白血病、P388白血病、艾氏腹水瘤(EAT)和刘易斯肺癌(LLC)的抗肿瘤活性。将结果与3β-羟基-17α-氮杂-D-高-5α-雄甾烷-17-酮的对-[N,N-双(2-氯乙基)氨基]苯乙酸酯的结果进行了比较。上述化合物还在体外对L1210、P388、EAT和BHX细胞培养物进行了测试。发现所有化合物均具有活性,并对它们的构效关系进行了讨论。